Select Page

Press

  • Employment Opportunities at a Cutting Edge Biotech Company in Providence

    Employment Opportunities at a Cutting Edge Biotech Company in Providence

    Posted on January 4, 2014 by Annie De Groot
    Why work at EpiVax? Members of the EpiVax team strive to see beyond the horizon, desiring to be part of an effort that is bigger than themselves by contributing to improving human health by moving science forward.  In the long term, we aim to leave behind a legacy for the next generation, and we therefore continually ...
    Read more
  • H7N9 is back - now in Hong Kong (& Shenzhen, China)

    H7N9 is back – now in Hong Kong (& Shenzhen, China)

    Posted on December 8, 2013 by Annie De Groot
    Date: Sun 8 Dec 2013 Story communicated by and reposted from: ProMED-mail South China Morning Post 19 people who came into contact with Hong Kong’s 2nd H7N9 flu patient are being kept in isolation in a hospital and at a holiday camp. They include 13 Tuen Mun Hospital patients who were being cared for in beds close to the 80-year-old man when ...
    Read more
  • EpiVax Receives More Funding for Pompe's Research

    Posted on December 5, 2013 by Annie De Groot
    Seven RI Companies Receive $314,930 in SBIR Phase I Matching Grants Published on December 5, 2013 Seven Rhode Island companies are the first recipients of the Innovate Rhode Island Small Business Fund (IRISBF) matching grants for federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant recipients.  These firms have already received over $1.2 ...
    Read more
  • Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A (Full Article)

    Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A (Full Article)

    Posted on December 3, 2013 by Annie De Groot
    Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A Dreieich/ Germany, Rhode Island/ USA, 3 December 2013. Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The coagulation factor VIII used for ...
    Read more
  • Beyond Humanization: New EpiVax Publication (Open Access)

    Posted on November 26, 2013 by Annie De Groot
    Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics Expert Rev. Clin. Pharmacol. 6(6), 651–662 (2013) Abstract Immune responses to some monoclonal antibodies (mAbs) and biologic proteins interfere with their efficacy due to the development of anti-drug antibodies (ADA). In the case of mAbs, most ADA target ‘foreign’ sequences present in the complementarity determining regions (CDRs). ...
    Read more
  • Dr. Alan Rothman of iCubed Discusses new $21.4M in Grants for URI

    Posted on October 4, 2013 by Annie De Groot
    Dr. Alan Rothman of iCubed discusses two large grants, totaling $21.4 million dollars for The University of Rhode Island. He also comments on the current status of the government and the effects on academic groups obtaining grants. (interview starts at 1:15) Read the original PBN article on this topic. // _ // ]]>//
    Read more
  • EpiVax commits resources to bring its Tregitope platform to clinic

    Posted on September 25, 2013 by Annie De Groot
     https://convergenceri.com/ EpiVax commits resources to bring its Tregitope platform to clinic A pioneering firm in immunogenicity comes of age PHOTO BY SCOTT KINGSLEY Dr. Anne S. De Groot, CEO of EpiVax, Inc., is one of the original biotech pioneers in Rhode Island. Her firm’s slogan is “Science without Fear.” By Richard Asinof Posted 9/21/13 PROVIDENCE – At age 15, EpiVax is one of ...
    Read more
  • 7th Vaccine Renaissance Conference - Abstracts Due Sept 15

    7th Vaccine Renaissance Conference – Abstracts Due Sept 15

    Posted on August 22, 2013 by Annie De Groot
    Registration is now open and abstracts are being accpeted, for 7th Annual Vaccine Renaissance Conference Providence, RI Registration is now open for iCubed’s seventh annual Vaccine Renaissance Conference. The conference is slated for October 16-18, 2013 in Providence, Rhode Island. Abstracts are being accepted and the deadline is September 15th – send 250 word abstract to Patrick Lowney ...
    Read more
  • PBN: iCube's Dr. Alan Rothman Lands $11M Grant for Dengue

    Posted on August 5, 2013 by Annie De Groot
    PBN: URI dengue fever researcher wins $11M grant COURTESY WIKIMEDIA COMMONS MOSQUITOES CAN CARRY dengue fever, which URI Professor Alan Rothman will study with an $11.4 grant from the National Institutes of Health. By Patricia Daddona  PBN Staff Writer Posted 8/2/13 PROVIDENCE – A researcher of mosquito-borne illness at the University of Rhode Island has received an $11 million grant from ...
    Read more
  • New EpiVax Publication: Tregitope & AAV Vectors

    Posted on July 26, 2013 by Annie De Groot
      A Brand New EpiVax Publication is Now Online! Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes (Tregitopes) Immune responses directed against viral capsid proteins constitute a main safety concern in the use of adeno-associated virus (AAV) as gene transfer vectors in humans. Pharmacological immunosuppression has been proposed as a solution ...
    Read more
  • PBN: Vaccine development for H7N9 flu moving forward

    Posted on May 20, 2013 by Annie De Groot
    LIFE SCIENCES Vaccine development for H7N9 flu moving forward By Richard Asinof Contributing Writer Twitter: @RichardAsinof Posted 5/20/13 PROVIDENCE – It has been a very busy month and half for Dr. Anne S. De Groot and her team at EpiVax, a bioscience firm based in the Knowledge District, which celebrated its 15th birthday on May 17. De Groot, the chief science officer and ...
    Read more
  • Dr. Cousens & Dr. De Groot to Receive RI Bioscience Awards

    Posted on May 2, 2013 by Annie De Groot
    EpiVax Congratulates Dr. Leslie Cousens and Dr. Annie De Groot! Scientific Director of Protein Therapeutics and Lead Scientist on the Tregitope project at EpiVax, Dr. Leslie Cousens and EpiVax CEO/CSO Dr. Annie De Groot are two of five RI Bioscience Award winners for 2013! “The Tech Collective’s Rhode Island Bioscience Awards honor those who are innovating ...
    Read more
  • New EpiVax Publication: Tregitopes and T1D

    Posted on April 24, 2013 by Annie De Groot
    Application of IgG-Derived Natural Treg Epitopes (IgG Tregitopes) to Antigen-Specific Tolerance Induction in a Murine Model of Type 1 Diabetes Abstract HLA class II-restricted regulatory T cell (Treg) epitopes in IgG (also called “Tregitopes”) have been reported to suppress immune responses to coadministered antigens by stimulating the expansion of natural Tregs (nTregs). Here we evaluate their impact ...
    Read more
  • BIOATLA COMBINES EPIVAX’S IMMUNOGENICITY SCREENING INTO THEIR EXPRESS HUMANIZATION PLATFORM

    Posted on April 23, 2013 by Annie De Groot
                                                              BIOATLA COMBINES EPIVAX’S IMMUNOGENICITY SCREENING INTO THEIR EXPRESS HUMANIZATIONTM PLATFORM  EpiVax BioAtla Collaboration Page Providence and San Diego, 24 April 2013 – EpiVax Inc., an unique immunology company with a strong focus ...
    Read more
  • EpiVax H7N9 - Vaccine Blueprint

    EpiVax H7N9 – Vaccine Blueprint

    Posted on April 16, 2013 by Annie De Groot
    An Update on EpiVax’ H7N9 “FastVax” Progress EpiVax scientists are currently in discussions with groups in China, Canada and the US about producing a vaccine. Here we highlight a few key points about the current progress of EpiVax’ FastVax vaccine design: (1) While H7N9 influenza may be mutable, selecting highly conserved and immunogenic components for vaccines is our ...
    Read more

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here